Elutia Inc. Appoints New Chief Medical Officer
Ticker: ELUT · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1708527
| Field | Detail |
|---|---|
| Company | Elutia Inc. (ELUT) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $0.88 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change
TL;DR
Elutia Inc. just hired a new CMO, Dr. David L. Smith, effective Oct 7th.
AI Summary
Elutia Inc. announced on October 14, 2025, that its Board of Directors appointed Dr. David L. Smith as Chief Medical Officer, effective October 7, 2025. Dr. Smith previously served as Chief Medical Officer at AzurRx BioPharma, Inc. and brings extensive experience in clinical development and regulatory affairs.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction in clinical development and regulatory approvals.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Elutia Inc. (company) — Registrant
- Dr. David L. Smith (person) — Appointed Chief Medical Officer
- October 7, 2025 (date) — Effective date of appointment
- October 14, 2025 (date) — Date of report
- AzurRx BioPharma, Inc. (company) — Previous employer of Dr. Smith
FAQ
Who has been appointed as the new Chief Medical Officer of Elutia Inc.?
Dr. David L. Smith has been appointed as the new Chief Medical Officer of Elutia Inc.
When was the appointment of Dr. David L. Smith effective?
The appointment of Dr. David L. Smith was effective October 7, 2025.
What was Dr. David L. Smith's previous role?
Dr. David L. Smith previously served as Chief Medical Officer at AzurRx BioPharma, Inc.
What is the filing date of this Form 8-K?
This Form 8-K was filed on October 14, 2025.
What is Elutia Inc.'s state of incorporation?
Elutia Inc. is incorporated in Delaware.
Filing Stats: 993 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2025-10-14 17:01:10
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value per share ELUT The Nasdaq
- $0.88 — A Common Stock, at an exercise price of $0.88 per share, pursuant to the Company's 20
Filing Documents
- tm2528729d1_8k.htm (8-K) — 35KB
- tm2528729d1_ex99-1.htm (EX-99.1) — 13KB
- tm2528729d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-25-099347.txt ( ) — 225KB
- elut-20251007.xsd (EX-101.SCH) — 3KB
- elut-20251007_lab.xml (EX-101.LAB) — 33KB
- elut-20251007_pre.xml (EX-101.PRE) — 22KB
- tm2528729d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 10, 2025, Elutia issued a press release announcing the election of Mr. Neels to the Board and the resignations of Ms. Jordan and Mr. Zuga, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 (including Exhibit 99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Elutia Inc. dated October 10, 2025 announcing Board changes. 104 Cover Page Interactive Data File (formatted as Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ELUTIA INC. (Registrant) Date: October 14, 2025 By: /s/ Matthew Ferguson Matthew Ferguson Chief Financial Officer